Highlights

• SomnoMed develops custom oral appliances for obstructive sleep apnoea patients seeking alternatives to traditional treatments.
• FY26 results showed improving profitability with EBITDA growth exceeding Revenue growth.
• The company launched Virtus to expand its sleep apnoea and bruxism treatment offering.
• Future performance depends on North American growth, product adoption and continued Margin improvement.

SomnoMed (ASX:SOM) develops custom oral appliances for obstructive sleep apnoea, providing dental-style devices designed to help keep airways open during sleep. The company operates within the global sleep-disorder market, offering an alternative treatment option for…